Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies
Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens
Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance
Novel CLL-1-directed CAR-T cells Mediate Potent Antigen-specific Cytolytic Activity in
Mouse Models of Acute Myeloid Leukemia
Clinical Holds for Cell and Gene Therapy Trials: Risks, Impact, and Lessons Learned
GUMM: A Purpose-Built Computational Workflow for Single Cell Genotyping of Gene Editing Experiments
Development of a Gene Edited Next-Generation Hematopoietic Cell Transplant to Enable Acute Myeloid Leukemia Treatment by Solving Off-Tumor Toxicity
A Single Cell DNA Sequencing Resource and Computational Approach to Quantify CRISPR-Cas9 Gene Editing Allelism
